AVKARE Inc.

Complete recall history across all FDA and CPSC categories — 33 total recalls

AVKARE Inc. appears in recall records across 1 category. This page consolidates all FDA food, drug, and medical device enforcement actions, plus CPSC consumer product recalls associated with this company. Recall data is sourced from openFDA and CPSC public databases.

Drug Recalls (33)

FDA drug safety enforcement actions by AVKARE Inc.

Date Product Reason Class
Jul 20, 2022 Lamotrigine Tablets, USP 100 mg, 1000-count bottles, Rx Only, Manufactured fo... Labeling: Label Error on Declared Strength Class III
Jun 9, 2021 Phytonadione Tablets 5 mg, Rx Only, 30 Tablets (3x10) Unit Dose, Manufactured... Failed Impurities Specification: Out of specification when measuring the impu... Class III
Dec 7, 2020 Sildenafil Tablets USP 100 mg, Rx Only, 100-count Bottle, Manufactured for: A... Product mix-up: Bottles of sildenafil and trazodone were inadvertently packag... Class II
Dec 7, 2020 TraZODONE Hydrochloride Tablets USP 100 mg, Rx Only, 1000-count Bottle, Manuf... Product mix-up: Bottles of sildenafil and trazodone were inadvertently packag... Class I
Oct 30, 2020 Mesalamine Delayed-Release Tablets, USP 1.2 gram (Once-Daily), 120 Tablets bo... Failed Dissolution Specifications Class II
Jun 4, 2020 Metformin Hydrochloride Extended-Release Tablets, USP 750 mg a) 90 count (NDC... CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity... Class II
Jun 4, 2020 Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, a) 50 count (ND... CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity... Class II
May 28, 2020 Lamotrigine Tablets, USP, 150 mg, Rx Only, a) 60 count Bottle, NDC 42291-368-... Presence of Foreign Substance consistent with granules from desiccant packs u... Class III
Jan 7, 2020 Dutasteride Capsules, 0.5 mg, 30 Capsules (6 X 5) Unit Dose per carton, Rx On... Failed Impurities/Degradation Specifications: High out of specification resul... Class II
Nov 14, 2019 AVKARE Ranitidine Tablets, USP 300 mg Rx Only NDC Manufactured for: AvKARE, I... CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API Class II
Nov 14, 2019 AVKARE Ranitidine Tablets, USP 150 mg Rx Only Manufactured for: AvKARE, Inc. ... CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API Class II
Oct 17, 2019 AVKARE Ranitidine Hydrochloride Capsules 300 mg 500 Capsules Rx Only NDC 4229... CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API Class II
Oct 17, 2019 AVKARE Ranitidine Hydrochloride Capsules 150 mg 500 Capsules Rx Only NDC 4229... CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API Class II
Aug 28, 2019 AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Table... Failed Stability Specifications. Class II
Apr 24, 2019 Losartan Potassium Tablets USP 25 mg 50 tablets (5x10) Unit Dose Rx Only NDC ... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... Class II
Apr 24, 2019 Losartan Potassium Tablets USP 50 mg 50 tablets (5x10) Unit Dose Rx Only NDC ... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... Class II
Apr 3, 2019 Telmisartan and Amlodipine Tablets 80 mg/5 mg, 30 tablets, Rx Only, Manufact... Failed Impurities/Degradation Specifications; 18 month long term stability st... Class III
Mar 5, 2019 Losartan Potassium and Hydrochlorothiazide Tablets, USP 50 mg/12.5 mg 50 Tabl... CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) ... Class II
Mar 5, 2019 Losartan Potassium Tablets USP 50 mg 50 Tablets (5x10) Unit Dose boxes, Rx On... CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) ... Class II
Mar 5, 2019 Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 50 Tab... CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) ... Class II
Mar 1, 2019 Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 4... Failed Dissolution Specifications Class III
Nov 20, 2018 Germ Bloc Health Hand Sanitizer Foam (benzalkonium chloride 0.13%) 7.5fl.oz./... Microbial Contamination of Non-Sterile Product: Presence of Pseudomonas aerug... Class II
Aug 14, 2018 Valsartan Tablets, USP 80 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-78... CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug... Class II
Aug 14, 2018 Valsartan Tablets, USP 320 mg Rx Only 30 Tablets (6x5) Unit Dose NDC 50268-78... CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug... Class II
Aug 14, 2018 Valsartan Tablets, USP 160 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-7... CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug... Class II
Aug 14, 2018 Valsartan Tablets, USP 40 mg Rx Only NDC 50268-783-15 50 Tablets (5x10) Unit ... CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug... Class II
Mar 30, 2018 Amantadine HCl Capsules, USP, 100 mg, 50 Capsules (5x10) Unite Dose, Rx Only,... Failed Dissolution Specifications Class II
Jan 3, 2018 Lovastatin Tablets USP, 40 mg, 50 Tablets (5x10) Unit Dose carton, Rx only, M... Failed Dissolution Specifications: Low out of specification results for disso... Class II
Oct 6, 2017 Duloxetine Delayed-release Capsules USP, 20 mg, 50 Capsules (5 x 10) Unit Dos... Failed Impurities/Degradation Specifications: slightly elevated levels of pht... Class II
Jul 19, 2017 Voriconazole Tablets, 200 mg, 20-count cartons (4 x 5) Unit Dose, Rx only, Ma... Failed impurities/degradation specifications: Out of specification for a rela... Class III
Feb 15, 2017 Famciclovir tablets, 500 mg, packaged in 30-count unit dose cartons, Rx only,... Failed impurities/ degradation specifications: Product was above specificatio... Class II
Feb 27, 2015 Quinapril Tablets USP, 5 mg, Rx only, 50 tablets (5 X 10) unit dose pack, Man... Subpotent Drug Class III
Feb 27, 2015 Quinapril Tablets USP, 40 mg, Rx only, 50 tablets (5 X 10) unit dose pack, Ma... Subpotent Drug Class III

Frequently Asked Questions

A high number of recalls does not necessarily indicate that a company is unsafe. Large manufacturers that produce thousands of products across multiple categories will statistically appear in recall databases more frequently. What matters more is the severity of each recall (Class I being the most serious), the speed of response, and whether the company proactively identified and addressed the issue. Companies with robust safety programs often catch problems earlier.

Food, drug, and medical device recall data comes from the FDA's openFDA enforcement database, which contains all FDA enforcement reports. Consumer product recall data comes from the U.S. Consumer Product Safety Commission (CPSC). Both sources are public government databases that are updated regularly. RecallCheck aggregates these sources to provide a unified view of a company's recall history.

The FDA classifies recalls into three categories. Class I is the most serious — there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. Class II means the product may cause temporary or medically reversible health problems, or the probability of serious consequences is remote. Class III is the least serious — the product is unlikely to cause adverse health consequences. CPSC product recalls do not use this classification system.

Yes. You can search for any company using the firm/manufacturer pages for each category: Food Firms, Drug Firms, Device Firms, or Product Manufacturers. You can also use the search functionality on any browse page to find recalls by company name.

Explore More Recalls

Search recalls by category, state, reason, or firm across all our databases.